Century Therapeutics, Inc.(IPSC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,812 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
IPSC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Century Therapeutics, Inc. (IPSC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IPSC at 43.5/100 on a 32-signal composite quality model, placing it at rank #1,812 of 2,879 stocks — the bottom half of the AI-ranked universe. IPSC scores in the top quartile across revenue growth (99.9), institutional flow (99.8). Areas of concern include free cash flow (9.2) and balance sheet strength (23.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Century Therapeutics, Inc. reports net income of $-21.6M, free cash flow of $-25.8M. Top institutional holders of IPSC by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management,, Versant Venture Management,, based on the most recent SEC filings. IPSC trades on the Nasdaq exchange and files with the SEC under CIK 1850119. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IPSC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Century Therapeutics, Inc. directly from SEC EDGAR. Century Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 4 and 44 since 2023, currently 43.5 — an improving long-term trajectory across 22 quarterly and live scoring snapshots.
Net Income
Q1 2026
$-21.6M
Free Cash Flow
Q1 2026
$-25.8M
ROIC
Q1 2026
-8.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+194.8% YoYNet Income
+7.4% YoYOperating Income
+5.7% YoYEPS (Diluted)
+30.0% YoYTotal Assets
-2.1% YoYTotal Debt
Op. Cash Flow
-24.7% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $6.6M +194.8% | $2.2M -57.0% | $5.2M | — | — |
| Net Income | $-126.6M +7.4% | $-136.7M -4.4% | $-130.9M -36.6% | $-95.8M -78.9% | $-53.6M |
| Operating Income | $-138.1M +5.7% | $-146.5M -9.5% | $-133.8M -41.0% | $-94.9M -76.0% | $-53.9M |
| EPS (Diluted) | $-0.81 +30.0% | $-1.15 +22.3% | $-1.48 +0.0% | $-1.48 -4.0% | $-1.42 |
| Total Assets | $353.2M -2.1% | $360.7M -25.9% | $486.5M +11.2% | $437.4M +309.6% | $106.8M |
| Total Debt | — | — | $16.9M +47.8% | $11.4M +18.7% | $9.6M |
| Operating Cash Flow | $-110.1M -24.7% | $-88.3M -728.7% | $14.1M +115.8% | $-89.0M -115.7% | $-41.3M |
Get alerted when IPSC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Century Therapeutics, Inc. including:
Top Institutional Holders of IPSC
RA CAPITAL MANAGEMENT, L.P.
$40.1M17,754,430 shTCG Crossover Management, LLC
$39.0M17,754,430 shVersant Venture Management, LLC
$27.5M12,166,109 shDeep Track Capital, LP
$21.4M9,487,745 shCommodore Capital LP
$19.7M8,695,652 shRTW INVESTMENTS, LP
$19.7M8,695,652 shVR Adviser, LLC
$19.7M8,695,652 shPoint72 Asset Management, L.P.
$13.5M5,964,678 shVANGUARD CAPITAL MANAGEMENT LLC
$12.9M5,686,204 shBALYASNY ASSET MANAGEMENT L.P.
$11.3M5,017,733 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $40.1M | 17,754,430 |
| TCG Crossover Management, LLC | $39.0M | 17,754,430 |
| Versant Venture Management, LLC | $27.5M | 12,166,109 |
| Deep Track Capital, LP | $21.4M | 9,487,745 |
| Commodore Capital LP | $19.7M | 8,695,652 |
| RTW INVESTMENTS, LP | $19.7M | 8,695,652 |
| VR Adviser, LLC | $19.7M | 8,695,652 |
| Point72 Asset Management, L.P. | $13.5M | 5,964,678 |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.9M | 5,686,204 |
| BALYASNY ASSET MANAGEMENT L.P. | $11.3M | 5,017,733 |
More Healthcare Companies
View all Healthcare →Put IPSC on your watchlist
Track score changes the day Century Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IPSC a good stock to buy?
13F Pro's AI-powered analysis of Century Therapeutics, Inc. (IPSC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IPSC are available on the IPSC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own IPSC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IPSC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Century Therapeutics, Inc.'s investment landscape.